ArticlePharmaceutics2021
Multivesicular Liposomes for Glucose-Responsive Insulin Delivery.
Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Fabrication of vitamin BInternational journal of pharmaceutics: X · 2026Article
- Glucose-Responsive Nanomedicine in Diabetes Therapy: Emerging Advances and Clinical Prospects.Journal of functional biomaterials · 2026Review
- Lipid-Based Delivery Systems for Therapeutic Glycoproteins: Current Advances, Challenges, and Future Perspectives.Pharmaceutics · 2026Review
- Smart nanomaterials enabling drug delivery and glucose monitoring for diabetes management.Discover nano · 2026Review
- Liposome-Based Drug Delivery for Diabetes: Therapeutic Applications and a Nanomedicine Perspective on Diabetic Complications.International journal of nanomedicine · 2026Review
- Smart Antidiabetic Nanomedicine: A Revolutionized Therapeutic Approach for Treatment of Diabetes Mellitus.Bioengineering (Basel, Switzerland) · 2025Review
- Liposomal Nanosystems Versus Hydrogels in the Prevention and Treatment of Metabolic Diseases.Gels (Basel, Switzerland) · 2025Review
- Advances in Nanomedicine for Precision Insulin Delivery.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Determination of vat-photopolymerization parameters for microneedles fabrication and characterization of HPMC/PVP K90 dissolving microneedles utilizing 3D-printed mold.Scientific reports · 2024Article
- A review on oral novel delivery systems of insulin through the novel delivery system formulations: A review.SAGE open medicine · 2024Review
- Organic and Biogenic Nanocarriers as Bio-Friendly Systems for Bioactive Compounds' Delivery: State-of-the Art and Challenges.Materials (Basel, Switzerland) · 2023Review
- Current Technologies for Managing Type 1 Diabetes Mellitus and Their Impact on Quality of Life-A Narrative Review.Life (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An intelligent insulin delivery system is highly desirable for diabetes management. Herein, we developed a novel glucose-responsive multivesicular liposome (MVL) for self-regulated insulin delivery using the double emulsion method. Glucose-responsive MVLs could effectively regulate insulin release in response to fluctuating glucose concentrations in vitro. Notably, in situ released glucose oxidase catalyzed glucose enrichment on the MVL surface, based on the combination of (3-fluoro-4-((octyloxy)carbonyl)phenyl)boronic acid and glucose. The outer MVL membrane was destroyed when triggered by the local acidic and H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.